Want to see JP:6190 full AI Analyst Report?

PhoenixBio Co., Ltd. (6190) Price & Analysis

0 Followers

6190 Stock Chart & Stats

¥484.00

¥9.00(2.79%)

At close: Jan 08 4:00 PM EST

¥484.00

¥9.00(2.79%)

Day’s Range― - ―

52-Week Range¥321.00 - ¥724.00

Previous CloseN/A

Volume3.50K

Average Volume (3M)360.67K

Market Cap

¥1.37B

Enterprise Value¥853.58M

Total Cash (Recent Filing)¥1.15B

Total Debt (Recent Filing)¥486.64M

Price to Earnings (P/E)11.0

Beta0.53

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)30.80

Shares Outstanding4,076,933

10 Day Avg. Volume91,460

30 Day Avg. Volume360,670

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.14

P/FCF Ratio31.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margins & Recent ProfitabilitySustained ~76% gross margins indicate strong pricing power or an asset-light mix in specialized animal supplies and services. This margin profile supports durable profitability even with revenue variability, providing scope to fund R&D and specialized operations without relying solely on top-line growth.

Improving Leverage And CapitalizationA debt-to-equity near 0.31 and positive ROE signal improving balance-sheet resilience versus prior stressed periods. Lower leverage reduces refinancing risk and interest burden, enabling steadier investment in facilities and compliance, which is critical for a regulated life-science services provider over the medium term.

Niche, Mission-critical Business ModelSpecialized disease-model animals and contract support are high-barrier, recurring inputs for drug discovery. This niche creates customer stickiness, technical know-how defensibility, and recurring revenue potential from long-term research programs, supporting stable demand across development cycles.

Bears Say

Inconsistent Cash GenerationRepeated negative operating and free cash flows in prior years, and operating cash covering only ~18% of earnings, signal earnings are not reliably converting to cash. This limits capacity to self-fund growth, capital expenditures, or buffer downturns, increasing reliance on external financing.

Multi-year Earnings VolatilityWide swings between profits and losses across multiple years reduce predictability of margins, cash flow and investment returns. For customers, suppliers, and lenders, this variability raises perceived risk and can raise funding costs or limit long-term contracts that require steady operational footprints.

Limited ScaleA small headcount implies limited operational scale and narrower resource bandwidth versus larger CROs. This constrains capacity to expand simultaneously across multiple large projects, absorb regulatory cost increases, or diversify customer concentration, leaving the company exposed to idiosyncratic demand shocks.

6190 FAQ

What was PhoenixBio Co., Ltd.’s price range in the past 12 months?

PhoenixBio Co., Ltd. lowest stock price was ¥321.00 and its highest was ¥724.00 in the past 12 months.

What is PhoenixBio Co., Ltd.’s market cap?

PhoenixBio Co., Ltd.’s market cap is ¥1.37B.

When is PhoenixBio Co., Ltd.’s upcoming earnings report date?

PhoenixBio Co., Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 29 days.

How were PhoenixBio Co., Ltd.’s earnings last quarter?

PhoenixBio Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥7.87 earnings per share for the quarter, beating the consensus estimate of N/A by ¥7.87.

Is PhoenixBio Co., Ltd. overvalued?

According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PhoenixBio Co., Ltd. pay dividends?

PhoenixBio Co., Ltd. does not currently pay dividends.

What is PhoenixBio Co., Ltd.’s EPS estimate?

PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PhoenixBio Co., Ltd. have?

PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.

What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?

PhoenixBio Co., Ltd. reported an EPS of ¥7.87 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.778%.

Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?

Currently, no hedge funds are holding shares in JP:6190

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.